Distinct Transcriptional Landscapes Identified by Radiographic Response in Metastatic Triple-Negative Breast Cancer Treated with Carboplatin, Nab-Paclitaxel, and Pembrolizumab in a Single-Arm Phase II Trial

A single arm, Phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safety/tolerability, and identify pathologic and transcriptomic correlates of response to therapy. Overall design: Single arm phase II clinical trial involving treatment of mTNBC patients with carboplatin, nab-paclitaxel, and pembrolizumab (CNP) to assess the overall response rate (ORR), overall and progression-free survival (OS, PFS), and toxicity profile associated with this particular combination of chemo-immunotherapeutic agents.